ANI Pharmaceuticals (ANIP) Expected to Announce Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is expected to be posting its quarterly earnings results before the market opens on Friday, February 28th. Analysts expect ANI Pharmaceuticals to post earnings of $1.41 per share and revenue of $175.36 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $54.51 on Wednesday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -99.11 and a beta of 0.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm has a 50 day simple moving average of $57.03 and a 200 day simple moving average of $58.17. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,300 shares of company stock worth $584,009 over the last three months. 12.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on ANIP shares. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 5th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.